Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resveratrol for Endothelial Dysfunction in Type 2 Diabetes
NCT07569744Completed
- Sponsor
- Universitas Sriwijaya
- Start
- May 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in type 2 diabetes mellitus (T2DM) and endothelial dysfunction comparing Resveratrol Group with Placebo Group (2 arms). Primary endpoints: Flow-Mediated Dilatation of the Brachial Artery at 12 weeks and Serum Endothelial Nitric Oxide Synthase Levels at 12 weeks. Started May 2026; status: completed.
02
Drugs
resveratrol
03
Conditions
type 2 diabetes mellitus (T2DM)endothelial dysfunction
Beyond the preview
Go deeper on NCT07569744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569744.